// App-Quantinova.ai

P064 : Long-term Reduction Of Relapse Rate And Confirmed Disability Progression After 6 Years Of Ocrelizumab Treatment In Patients With Relapsing MS

Researchers

Presenter

  • S. L. Hauser

Principal Investigators

  • L. Kappos

  • G. Giovannoni

  • X. Montalban

  • H. Koendgen

  • Q. Wang

  • M. Manfrini

  • J. Wolinsky

Medical Centers

  • University of California, San Francisco, CA

  • University Hospital Basel, Basel, Switzerland

  • Queen Mary University of London, London, United Kingdom

  • University of Toronto, Toronto, ON, Canada

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • UTHealth McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX

Locations

  • United States

  • Switzerland

  • United Kingdom

  • Canada

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Dermatology

  • Genetic Disorder

Disease

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • GC Vitamin D Binding Protein

Drug/Treatment

  • Ocrelizumab

  • Interferon

  • IFN-lambda

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01247324

  • NCT01412333

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved